This important study advances a new computational approach to measure and visualize gene expression specificity across different tissues and cell types. The framework is potentially helpful for ...
Strong participation in recent $33 million common stock offering highlights investor confidence in late-stage clinical momentum and commercial ...
Armatus Bio, a late-preclinical stage biotech innovator developing vectorized RNAi medicines in neuromuscular disorders, today announced the publication of foundational data in Molecular Therapy ...
BYD’s oldest model has received a heavy facelift, bringing more power, space and technology. Cameron Richards has been ...
Cue Biopharma, Inc. ( CUE) Discusses CUE-401 R&D Progress and Mechanism for Autoimmune and Inflammatory Diseases April 7, 2026 10:00 AM EDT Lucinda Warren - Interim CEO, Interim President,Principal ...
In a bar, a poet meets the man behind the drug that saved his life — discovering how science, faith and chance created a ...
ARCHER II Topline Pivotal Phase 3 Data in Geographic Atrophy (GA) Expected Q4 2026; Vonaprument has Potential to Be the First Vision-Preserving ...
In the race of innovative drug R&D, whether for antibodies, peptides, or novel binding proteins, the efficiency of early-stage molecule discovery is always the key factor determining project success ...
The Office of Undergraduate Research organizes the Symposium of Student Scholars twice per year, offering students a unique ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results